Key points are not available for this paper at this time.
"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy." Leukemia & Lymphoma, 61(14), pp. 3532–3533
Othman et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: